STOCK TITAN

Liquidia Corp - LQDA STOCK NEWS

Welcome to our dedicated news page for Liquidia (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liquidia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liquidia's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
offering
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.19%
Tags
offering
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.19%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
Liquidia Corp

Nasdaq:LQDA

LQDA Rankings

LQDA Stock Data

1.12B
49.94M
12.42%
51.18%
9.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Durham

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.